Phocas Financial Corp. Buys New Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Phocas Financial Corp. bought a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 209,582 shares of the company's stock, valued at approximately $2,016,000. Phocas Financial Corp. owned approximately 0.14% of MiMedx Group at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. IMG Wealth Management Inc. purchased a new position in MiMedx Group in the 4th quarter valued at approximately $28,000. Virtus Fund Advisers LLC purchased a new position in MiMedx Group in the 4th quarter valued at approximately $35,000. Van ECK Associates Corp purchased a new position in MiMedx Group in the 4th quarter valued at approximately $40,000. Tower Research Capital LLC TRC increased its stake in MiMedx Group by 77.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after purchasing an additional 2,837 shares in the last quarter. Finally, AlphaQuest LLC purchased a new position in MiMedx Group in the 4th quarter valued at approximately $88,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO William Frank Iv Hulse sold 81,446 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $7.80, for a total value of $635,278.80. Following the sale, the chief accounting officer now owns 494,774 shares in the company, valued at $3,859,237.20. This trade represents a 14.13% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 141,907 shares of company stock worth $1,112,580. 1.70% of the stock is owned by insiders.

MiMedx Group Price Performance

NASDAQ:MDXG traded down $0.08 during trading hours on Friday, reaching $6.47. 571,892 shares of the company traded hands, compared to its average volume of 690,770. The firm's 50-day moving average is $6.94 and its 200-day moving average is $8.13. The stock has a market cap of $955.63 million, a P/E ratio of 11.76 and a beta of 1.85. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, meeting analysts' consensus estimates of $0.06. The firm had revenue of $88.21 million for the quarter, compared to analysts' expectations of $86.32 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Equities research analysts expect that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MDXG. Wall Street Zen downgraded MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.